- Previous Close
118.19 - Open
117.78 - Bid 120.33 x 1000
- Ask 120.59 x 1000
- Day's Range
116.60 - 122.40 - 52 Week Range
62.55 - 170.47 - Volume
2,613,165 - Avg. Volume
3,962,519 - Market Cap (intraday)
46.142B - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-15.60 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
133.95
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA
View More
Performance Overview: MRNA
Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA
View MoreValuation Measures
Market Cap
45.30B
Enterprise Value
38.01B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.86
Price/Book (mrq)
3.53
Enterprise Value/Revenue
7.48
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-115.82%
Return on Assets (ttm)
-15.72%
Return on Equity (ttm)
-37.68%
Revenue (ttm)
5.15B
Net Income Avi to Common (ttm)
-5.97B
Diluted EPS (ttm)
-15.60
Balance Sheet and Cash Flow
Total Cash (mrq)
8.52B
Total Debt/Equity (mrq)
9.65%
Levered Free Cash Flow (ttm)
-1.95B
Research Analysis: MRNA
View MoreCompany Insights: MRNA
MRNA does not have Company Insights
Research Reports: MRNA
View MoreGSK, Pfizer, and Moderna: New RSV Vaccine Guidance Shrinks, but Long-Term Potential Remains
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetRaising target price to $150
Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 5,150 employees.
RatingPrice TargetAt midday Thursday, the S&P 500 was at a fresh record
At midday Thursday, the S&P 500 was at a fresh record as the boom in artificial intelligence stocks continues. Elsewhere, housing starts for May came in at 1.28 million, below the 1.37 million consensus. Permits came in at 1.39 million, also below the consensus of 1.45 million. High interest rates continue to impact the housing market, with recent telltale signs including a drop in sales of existing homes, a decline in homebuilder sentiment, and fewer homes delivered according to the 2Q earnings report from KB Home.
Moderna: RSV Vaccine Approval Marks Beginning of Expansion Beyond Covid
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice Target